# Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

> **NCT06625190** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Florida** · enrollment: 27 (estimated)

## Conditions studied

- Neuroblastoma
- Rhabdomyosarcoma
- Synovial Sarcoma
- Peripheral Nerve Sheath Tumors
- Clear Cell Sarcoma
- Alveolar Soft Part Sarcoma
- Desmoplastic Small Round Cell Tumor
- Chordoma
- Rhabdoid Tumor
- Epithelioid Sarcoma
- Myoepithelial Tumor
- Osteosarcoma
- Ewing Sarcoma

## Interventions

- **DEVICE:** Miltenyi CliniMACS Prodigy ® system
- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT06625190
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-11
- **Primary completion:** 2030-02
- **Final completion:** 2030-02
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06625190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06625190, "Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT06625190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*